VivoSim Labs (VIVS) Competitors $2.44 +0.57 (+30.48%) As of 08/29/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsSEC FilingsTrendsBuy This Stock VIVS vs. AIMD, IXHL, ATNF, NEUP, LEXX, MTEX, EDSA, CYCC, SYBX, and LSBShould you be buying VivoSim Labs stock or one of its competitors? The main competitors of VivoSim Labs include Ainos (AIMD), Incannex Healthcare (IXHL), 180 Life Sciences (ATNF), Neuphoria Therapeutics (NEUP), Lexaria Bioscience (LEXX), Mannatech (MTEX), Edesa Biotech (EDSA), Cyclacel Pharmaceuticals (CYCC), Synlogic (SYBX), and LakeShore Biopharma (LSB). These companies are all part of the "pharmaceutical products" industry. VivoSim Labs vs. Its Competitors Ainos Incannex Healthcare 180 Life Sciences Neuphoria Therapeutics Lexaria Bioscience Mannatech Edesa Biotech Cyclacel Pharmaceuticals Synlogic LakeShore Biopharma Ainos (NASDAQ:AIMD) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment. Does the media favor AIMD or VIVS? In the previous week, Ainos and Ainos both had 1 articles in the media. VivoSim Labs' average media sentiment score of 1.87 beat Ainos' score of 1.68 indicating that VivoSim Labs is being referred to more favorably in the news media. Company Overall Sentiment Ainos Very Positive VivoSim Labs Very Positive Is AIMD or VIVS more profitable? Ainos has a net margin of 0.00% compared to VivoSim Labs' net margin of -1,396.48%. VivoSim Labs' return on equity of -32.95% beat Ainos' return on equity.Company Net Margins Return on Equity Return on Assets AinosN/A -108.25% -56.94% VivoSim Labs -1,396.48%-32.95%-21.31% Which has better valuation and earnings, AIMD or VIVS? VivoSim Labs has higher revenue and earnings than Ainos. Ainos is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAinos$20K890.06-$14.86M-$4.99-0.77VivoSim Labs$140K45.31-$2.48M-$10.20-0.24 Do insiders and institutionals believe in AIMD or VIVS? 8.2% of VivoSim Labs shares are owned by institutional investors. 10.4% of Ainos shares are owned by company insiders. Comparatively, 3.7% of VivoSim Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, AIMD or VIVS? Ainos has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. SummaryVivoSim Labs beats Ainos on 7 of the 12 factors compared between the two stocks. Get VivoSim Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for VIVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIVS vs. The Competition Export to ExcelMetricVivoSim LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.34M$3.09B$5.72B$9.78BDividend YieldN/A2.28%4.10%4.04%P/E Ratio-0.2420.7883.2726.60Price / Sales45.31392.01536.98112.00Price / CashN/A44.2237.4459.26Price / Book0.668.0710.556.58Net Income-$2.48M-$53.98M$3.27B$265.95M7 Day Performance15.64%-0.88%0.40%0.17%1 Month Performance30.48%7.72%7.31%3.90%1 Year PerformanceN/A7.03%46.58%19.67% VivoSim Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIVSVivoSim LabsN/A$2.44+30.5%N/AN/A$6.34M$140K-0.2420Positive NewsGap DownHigh Trading VolumeAIMDAinos1.0023 of 5 stars$4.07-1.0%N/A+19.4%$18.97M$20K-0.8240Positive NewsIXHLIncannex Healthcare0.1225 of 5 stars$0.66-7.3%N/A-62.6%$18.90M$98K-0.533ATNF180 Life Sciences0.9491 of 5 stars$3.10+0.8%N/A+55.2%$18.72MN/A-0.217Gap DownNEUPNeuphoria Therapeutics1.9482 of 5 stars$9.45+14.3%$21.00+122.2%N/A$17.77M$10K0.00N/ANews CoverageAnalyst ForecastAnalyst RevisionGap UpLEXXLexaria Bioscience3.7211 of 5 stars$0.91-2.3%$4.00+340.5%-77.5%$17.76M$460K-1.367Positive NewsGap DownMTEXMannatech0.8912 of 5 stars$9.16+10.0%N/A+19.3%$17.40M$117.87M-4.49250Positive NewsGap UpEDSAEdesa Biotech2.1632 of 5 stars$2.45+0.8%$5.00+104.1%-47.6%$17.25MN/A-1.8620Positive NewsCYCCCyclacel Pharmaceuticals1.1089 of 5 stars$7.69+2.7%N/A-96.7%$17.22M$10K-0.0114Positive NewsSYBXSynlogic1.0954 of 5 stars$1.46-0.3%N/A-1.4%$17.02M$10K-18.1980Positive NewsLSBLakeShore Biopharma1.1193 of 5 stars$0.82+0.3%N/A-81.3%$16.93M$85.67M0.00773News Coverage Related Companies and Tools Related Companies Ainos Alternatives Incannex Healthcare Alternatives 180 Life Sciences Alternatives Neuphoria Therapeutics Alternatives Lexaria Bioscience Alternatives Mannatech Alternatives Edesa Biotech Alternatives Cyclacel Pharmaceuticals Alternatives Synlogic Alternatives LakeShore Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIVS) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VivoSim Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VivoSim Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIVS Stock Alerts